Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. We are advancing a diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. We are seeking a strategic and externally focused Executive Director, Global Market Development (Friedreich’s Ataxia) to lead the development and execution of Solid’s global key opinion leader (KOL) strategy for the FA program. This individual will play a critical role in shaping global external engagement, deepening scientific and clinical partnerships, and accelerating awareness and preparedness for Solid’s gene therapy programs. The role has a strong international focus, particularly across Europe, with exploratory engagement in the Middle East, and will require extensive global travel.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive